Ophthalmic Biopharmaceutical Ocuphire Pharma Shifts Focus To Gene Therapy Through Opus Genetics Stock Deal
Ophthalmic Biopharmaceutical Ocuphire Pharma Shifts Focus To Gene Therapy Through Opus Genetics Stock Deal
The combined company now has an expanded pipeline that includes multiple assets from its adeno-associated virus (AAV)-based gene therapy portfolio, which is currently being developed for IRDs, as well as Phentolamine Ophthalmic Solution 0.75%, which is currently being evaluated in presbyopia and dim (mesopic) light vision disturbances (sometimes referred to as DLD) after keratorefractive surgery.On Wednesday, Ocuphire Pharma, Inc. (NASDAQ:OCUP) announced the all-stock acquisition of Opus Genetics, Inc., a clinical-stage gene therapy company for inherited retinal diseases (IRDs).
周三，可口可乐制药公司（纳斯达克股票代码：OCUP）宣布全股票收购临床阶段基因治疗公司Opus Genetics，该公司专注于遗传性视网膜疾病（IRDs）。
The merger creates a biotech company focused on developing gene therapies for IRDs.
合并将打造一家专注于开发IRDs基因治疗的生物技术公司。
The combined company will be renamed Opus Genetics, effective October 23, 2024, and trade on the Nasdaq under the "IRD" ticker, effective October 24, 2024.
合并后的公司将于2024年10月23日更名为Opus Genetics，并于2024年10月24日起在纳斯达克交易，交易代码为“IRD”。
The combined company now has an expanded pipeline that includes multiple assets from its adeno-associated virus (AAV)-based gene therapy portfolio, which is currently being developed for IRDs, as well as Phentolamine Ophthalmic Solution 0.75%, which is currently being evaluated in presbyopia and dim (mesopic) light vision disturbances (sometimes referred to as DLD) after keratorefractive surgery.
合并后的公司现在拥有扩展的产品线，包括来自其基于腺相关病毒（AAV）的基因治疗组合的多种资产，目前正在为IRDs开发，以及Phentolamine眼科溶液0.75%，目前正在评估其用于老视和屈光手术后的暗光（mesopic）视力障碍（有时称为DLD）。
Due to the capital requirements and developmental timelines of APX3330 for non-proliferative diabetic retinopathy, the company will seek a partner to advance the clinical development of the late-stage diabetic retinopathy program. It will redirect its existing resources toward the acquired gene therapy programs.
由于非增殖性糖尿病视网膜病的APX3330的资金需求和发展时间表，该公司将寻找合作伙伴推进晚期糖尿病视网膜病项目的临床开发。它将重新调配现有资源用于收购的基因治疗项目。
The most advanced gene therapy candidate, OPGx-LCA5, is being developed for LCA5, an early-onset retinal degeneration, and an open-label, dose-escalation Phase 1/2 trial is ongoing.
最先进的基因治疗候选药OPGx-LCA5正在为早发性视网膜退化症LCA5开发，正在进行开放标签的剂量递增1/2期临床试验。
The trial has shown early clinical proof-of-concept, with new six-month data demonstrating visual improvement in three out of three adult patients participating in the trial.
该试验已显示出早期临床概念验证，最新六个月的数据显示，在参与试验的三名成年患者中有三名出现视觉改善。
The first pediatric patients in the Phase 1/2 trial are expected to be enrolled in the first quarter of 2025, and the first data are anticipated in the first quarter of 2025.
预计2025年第一季度将招募第一批参与1/2期试验的儿童患者，并预计2025年第一季度发布首批数据。
The expected cash runway of the combined company has been extended into 2026.
合并公司的预期现金推出时间已延长至2026年。
Ocuphire issued 5.2 million shares and 14.1 thousand shares of its convertible preferred stock.
Ocuphire发行了520万股普通股和1.41万股可转换优先股。
Following the issuances, Ocuphire will own approximately 58% of the combined company, and Opus Genetics will own approximately 42%.
在发行后，Ocuphire将拥有合并公司约58%的股份，而Opus Genetics将拥有约42%。
Price Action: OCUP stock is down 13.5% at $1.15 at last check Wednesday.
股价走势：OCUP股价在上周三最后交易时下跌了13.5%，为1.15美元。
- Coca-Cola Q3 Earnings: EPS Beat, Pricing Growth Offset By Volume Decline, Sees 10% Q4 Organic Revenue Growth.
- 可口可乐第三季度收益：每股收益超过预期，价格增长被销量下降抵消，预计第四季度有机营业收入增长10%。
Photo via Wikimedia Commons
照片通过Wikimedia Commons
